Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer
OncLive,
The combination of niraparib and dostarlimab produced a low overall response rate in patients with platinum-resistant ovarian…
MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
Overview of attention for article published in Journal of Clinical Oncology, June 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (78th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 9 Mendeley